AbbVie Inc vs United States Oil ETF — how do they compare? AbbVie Inc trades at $248.89 (market cap $438.19B), while United States Oil ETF trades at $127.17. The key difference: AbbVie Inc pays a 2.79% dividend while United States Oil ETF pays none. Which is the better fit depends on your goals.
| ABBV | USO | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | — |
52-Week High | $263.58 | $152.96 |
52-Week Low | $197.38 | $66.17 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
USO trades at $117.98, down 0.75% amid bearish technical signals with 13 sell indicators versus 4 buy signals. The stock faces pressure from Middle East tensions affecting oil markets, though RSI levels suggest potential oversold conditions. Recent news highlights ongoing Strait of Hormuz deadlock and declining Strategic Petroleum Reserve levels, creating volatility in energy sector valuations.
The outlook remains cautious with technical weakness and geopolitical uncertainty weighing on sentiment. Investment opportunity exists for contrarian buyers given oversold RSI levels, but risks include prolonged Middle East tensions and oil price volatility. Fundamental analysis is limited without current financial ratios available.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →